Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

Por Garrett, Joan T., Sutton, Cammie R., Kuba, María Gabriela, Cook, Rebecca S ., Arteaga, Carlos L.
Publicado em 2012

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

Por Chakrabarty, Anindita, Bhola, Neil E., Sutton, Cammie, Ghosh, Ritwik, Kuba, María Gabriela, Dave, Bhuvanesh, Chang, Jenny C., Arteaga, Carlos L.
Publicado em 2012

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers

Por Garrett, Joan T., Sutton, Cammie R., Kurupi, Richard, Bialucha, Carl Uli, Ettenberg, Seth A., Collins, Scott D., Sheng, Qing, Wallweber, Jerry, DeFazio-Eli, Lisa, Arteaga, Carlos L.
Publicado em 2013

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Por Hanker, Ariella B., Pfefferle, Adam D., Balko, Justin M., Kuba, María Gabriela, Young, Christian D., Sánchez, Violeta, Sutton, Cammie R., Cheng, Hailing, Perou, Charles M., Zhao, Jean J., Cook, Rebecca S., Arteaga, Carlos L.
Publicado em 2013

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin

Por Garner, Andrew P., Bialucha, Carl U., Sprague, Elizabeth R., Garrett, Joan T., Sheng, Qing, Li, Sharon, Sineshchekova, Olga, Saxena, Parmita, Sutton, Cammie R., Chen, Dongshu, Chen, Yan, Wang, Huiqin, Liang, Jinsheng, Das, Rita, Mosher, Rebecca, Gu, Jian, Huang, Alan, Haubst, Nicole, Zehetmeier, Carolin, Haberl, Manuela, Elis, Winfried, Kunz, Christian, Heidt, Analeah B., Herlihy, Kara, Murtie, Joshua, Schuller, Alwin, Arteaga, Carlos L., Sellers, William R., Ettenberg, Seth A.
Publicado em 2013